Recent 8-K filings for RGBP

• July 15, 2026, 4:18 PM ET litigation materiality 0.80 negative item 1.01item 8.01item 9.01

  Regen Biopharma settles $398,740 claims via share issuance; creates Series N preferred with 75M votes per share

  Court approved settlement with Trillium Partners: Regen will issue shares (common or Series A preferred) to satisfy $398,740 in claims; shares sold by plaintiff, 65% of net proceeds to plaintiff.

• March 4, 2026, 6:59 PM ET other material materiality 0.75 negative item 3.02 ◈ Equity Issuances

  Regen Biopharma issues 77.85M shares to settle $68,723 in debt and fees

  Issued 77,849,847 common shares between Feb 4-27, 2026 for $53,474 principal, $4,249 interest, $11,000 fees.

• February 2, 2026, 6:59 PM ET other material materiality 0.85 negative item 3.02 ◈ Equity Issuances ×3

  Regen Biopharma issues 21.4M shares in Jan 2026 for $69,550, massive dilution

  On Jan 15, 2026, issued 5,000,000 shares to satisfy $11,449 principal + $8,101 interest on convertible debt.

• January 21, 2026, 6:59 PM ET dividend materiality 0.50 neutral item 8.01

  Regen Biopharma declares 1:1 dividend of Series A Preferred stock for all share classes

  Board declared dividend of one share of Series A Preferred for each share of Common, Series A, AA, M, and NC Preferred owned.

• November 13, 2025, 6:59 PM ET other material materiality 0.35 neutral

  Regen BioPharma issues 23.68M common shares for cash and debt conversion in Oct-Nov 2025

  Oct 8, 2025: issued 6.8M shares for $68,000 cash.

• October 3, 2025, 7:59 PM ET other material materiality 0.75 negative item 1.01item 8.01item 9.01

  Regen BioPharma issues 40M shares to CEO and consultant for Phase I trial; shares vest on trial success

  Issued 20M shares to CEO David Koos for services in planned Phase I trial of HemaXellerate; shares vest upon trial completion.

• September 19, 2025, 7:59 PM ET other material materiality 0.20 neutral

  Regen Biopharma raises $58.2K via unregistered sales of 5.82M shares

  On Sep 15, 2025, issued 3,320,000 shares for $33,200 to an unaffiliated investor.

• August 7, 2025, 7:59 PM ET debt materiality 0.55 negative item 1.01item 3.02item 9.01

  Regen Biopharma issues $100K convertible note to Labrys Fund at 60% discount conversion

  Principal $100,000; net proceeds $85,000 after $15,000 original issue discount.

• August 1, 2025, 7:59 PM ET debt materiality 0.60 neutral item 1.01item 3.02item 9.01

  Regen Biopharma enters $130K convertible note financing with CFI Capital

  Issued a 6% convertible promissory note for $130,000 principal; $13,000 original issue discount, net proceeds $117,000.

• June 11, 2025, 7:59 PM ET other material materiality 0.70 neutral item 3.02item 9.01

  Regen Biopharma issues 10M shares to CEO in settlement of $50K accrued salary

  Issued 10,000,000 common shares to CEO David R. Koos as settlement for $50,000 of accrued unpaid salary.

• May 13, 2025, 7:59 PM ET other material materiality 0.70 negative item 4.02 ◈ Auditor Changes

  Regen Biopharma restates FY2024 financials; prior statements not reliable

  Non-reliance on unaudited FY2024 financials filed Nov 20, 2024; share compensation and derivative liability corrected.

• April 7, 2025, 7:59 PM ET other material materiality 0.60 neutral item 4.01 ◈ Auditor Changes ×2

  Regen Biopharma dismisses Bush & Associates, engages BCRG Group as new auditor

  Dismissed Bush and Associates CPA LLC as independent auditor effective March 31, 2025.

• November 29, 2024, 6:59 PM ET earnings materiality 0.85 negative item 2.02item 9.01

  Regen Biopharma FY2024 net loss $867k, revenue $237k; cash only $716

  Total revenues of $236,560 (incl. $110k related party); operating loss of $418,189.

• September 18, 2024, 7:59 PM ET dividend materiality 0.50 neutral item 8.01

  Regen Biopharma declares 1-for-1 stock dividend payable Nov 1

  Dividend of one common share for each share of common and Series A, AA, M, NC preferred stock held.

• September 13, 2024, 7:59 PM ET debt materiality 0.65 negative item 1.01item 9.01

  Regen Biopharma issues $250K promissory note to Coventry; $25K OID, convertible on default

  Principal amount $250K; original issue discount $25K, net proceeds $200K.

• May 29, 2024, 7:59 PM ET other material materiality 0.50 neutral item 4.01

  Regen Biopharma appoints Bush and Associates CPA as new independent auditor effective May 28, 2024

  Audit committee approved engagement of Bush and Associates CPA LLC as independent auditor on May 28, 2024.

• May 23, 2024, 7:59 PM ET other material materiality 0.35 neutral item 5.03item 8.01item 9.01

  Regen Biopharma declares Series A Preferred stock dividend and amends charter

  On May 20, 2024, amended Certificate of Incorporation to allow share dividends between classes/series.

• May 10, 2024, 7:59 PM ET other material materiality 0.60 negative item 4.01 ◈ Auditor Changes

  Regen Biopharma dismisses auditor BF Borgers due to SEC cease-and-desist order

  BF Borgers CPA PC dismissed as independent auditor effective May 10, 2024, following SEC order of May 3, 2024.

• April 29, 2024, 7:59 PM ET other material materiality 0.30 neutral item 1.01item 8.01item 3.02item 9.01

  Regen Biopharma issues 20,068 Series A Preferred shares for consulting; amends sublease

  Issued 20,068 Series A Preferred shares to Value Quest Inc. for one-year social media consulting services.

• February 9, 2024, 6:59 PM ET other material materiality 0.45 positive item 8.01

  Regen Biopharma files provisional patent for stem cell endothelial therapy to speed hematopoietic recovery

  Filed a provisional patent application with the USPTO on February 7, 2024.

• September 18, 2023, 7:59 PM ET other material materiality 0.50 neutral item 1.01item 9.01 ◈ Material Agreements ×3

  Regen Biopharma enters $175K promissory note and $10M equity line with Coventry

  Net proceeds $148,750 after $26,250 original issue discount; note matures March 2025.

• March 21, 2023, 7:59 PM ET other material materiality 0.60 negative item 3.02item 3.03

  Regen Biopharma issues 15K Series NC preferred shares to CEO with super-voting rights

  Issued 15,000 Series NC preferred shares to CEO David Koos to settle $10,050 debt.

• February 7, 2023, 6:59 PM ET other material materiality 0.60 negative item 5.03 ◈ Governance Changes ×3

  Regen Biopharma files 1-for-1500 reverse stock split and reduces preferred voting power

  Series AA preferred votes reduced to 7 per share; Series NC to 334 per share, effective March 6, 2023.

• November 21, 2022, 6:59 PM ET debt materiality 0.50 negative item 3.02

  Regen Biopharma issues 55.8M Series A Preferred shares to settle $376,711 in convertible debt

  Issued 55,809,233 Series A Preferred shares to satisfy $250,000 principal and $126,711 accrued interest on convertible promissory notes.

• November 18, 2022, 6:59 PM ET other material materiality 0.70 neutral item 3.02

  Regen Biopharma issues 101.9M Series A Preferred and 16.9M common shares in debt-for-equity swap

  Issued 101,880,008 shares of Series A Preferred to satisfy $511,500 convertible debt and $253,816 accrued interest.

• November 14, 2022, 6:59 PM ET other material materiality 0.40 neutral item 5.03item 8.01

  Regen Biopharma increases authorized Series A Preferred shares to 739M

  Series A Preferred Stock authorized shares increased to 739,000,000 via amendment to Certificate of Designation.

• September 20, 2022, 7:59 PM ET other material materiality 0.45 positive item 8.01item 9.01

  Regen BioPharma files patent on RNA/DNA dual checkpoint-gene silencing immunotherapy

  Filed provisional patent 'Dual Checkpoint Inhibitor Aptamer Based Therapeutics' targeting NR2F6 and Survivin gene silencing combined with PD-1 checkpoint inhibition.

• August 10, 2022, 7:59 PM ET other material materiality 0.40 neutral item 8.01

  Regen Biopharma subsidiary files provisional patent for CAR T-cell dedifferentiation method

  KCL Therapeutics, a wholly owned subsidiary, filed a provisional patent application with USPTO on August 9, 2022.

• July 20, 2022, 7:59 PM ET debt materiality 0.60 neutral item 3.02

  Regen Biopharma issues 54.5M shares to retire $180,552 convertible note with Coventry

  Issued 54,514,492 common shares to Coventry Enterprises LLC to satisfy $180,552 of convertible indebtedness.

• May 17, 2022, 7:59 PM ET other material materiality 0.65 neutral item 3.02item 8.01

  Regen Biopharma issues 100M shares to settle debt; subsidiary gets NR2F6 patent

  Issued 100M common shares to Coventry Enterprises LLC to satisfy $334,800 of convertible debt; note balance now $648,001.

• March 18, 2022, 7:59 PM ET other material materiality 0.50 neutral item 5.03

  Regen Biopharma increases authorized common shares to 5.8B; amends preferred share classes

  Authorized common shares increased from 4.8B to 5.8B, par value $0.0001.

• February 18, 2022, 6:59 PM ET other material materiality 0.60 negative item 8.01

  Regen Biopharma terminates acquisition negotiations for Canary Oncoceutics stake

  Terminated all negotiations to acquire 95% of Canary Oncoceutics.

• January 14, 2022, 6:59 PM ET other material materiality 0.25 neutral item 2.03item 9.01

  Regen Biopharma subleases office space from BST Partners controlled by CEO David Koos at $5,000/month

  Entered into month-to-month sublease with BST Partners for office space at 4700 Spring Street, Suite 304, La Mesa, CA starting January 14, 2022.

• December 22, 2021, 6:59 PM ET other material materiality 0.80 negative item 4.02

  Regen Biopharma restates June 30, 2021 financials; $1.9M revenue incorrectly recognized

  Board concluded Q2 and nine-month FY2021 financials should no longer be relied upon.

• December 20, 2021, 6:59 PM ET debt materiality 0.55 positive item 8.01

  Regen Biopharma pays down $1.02M of convertible notes, principal now $1.34M

  Principal indebtedness on convertible notes reduced from $2,364,075 (Jun 30) to $1,340,621 (Dec 13, 2021).

• November 12, 2021, 6:59 PM ET M&A materiality 0.70 neutral item 8.01

  Regen Biopharma signs non-binding LOI to acquire 95% of Canary Oncoceutics for $1M cash and stock

  Consideration: $1,000,000 cash plus common shares valued at RGBP's average share price pre-closing.

• November 5, 2021, 7:59 PM ET debt materiality 0.70 neutral item 8.01

  Regen Biopharma reduces convertible note principal by $967,830 via equity and cash

  Satisfied $967,830 of principal and $539,392 in fees/interest through 706M common shares, 23.7M Series A preferred, and $218,529 cash.

• November 4, 2021, 7:59 PM ET other material materiality 0.60 positive item 8.01

  Regen Biopharma awarded USPTO patent for NR2F6-silenced cord blood killer cell cancer therapy

  USPTO issued Patent No. 11,141,471 on Oct 12, 2021, covering universal donor checkpoint inhibitor silenced/gene edited cord blood killer cells.

• October 22, 2021, 7:59 PM ET other material materiality 0.85 positive item 8.01

  Regen BioPharma settles convertible notes for $43,529 cash to avoid potential issuance of 855M shares

  Settled convertible notes principal of $29,836 and accrued interest of $26,227 for $43,529.30 cash.

• October 19, 2021, 7:59 PM ET other material materiality 0.40 neutral item 1.01item 9.01

  Regen Biopharma engages Biotech Research Group for NR2F6 IP assessment at $25k total

  Engaged BRG to perform a GAP assessment of CRO work on NR2F6 checkpoint pre-clinical protocols, raw data, and completion report.

• September 27, 2021, 7:59 PM ET other material materiality 0.60 positive item 8.01

  Regen Biopharma receives USPTO Notice of Allowance for NR2F6 activity modulators patent

  Notice of Allowance issued Sept 23, 2021 for patent on small molecule agonists/antagonists of NR2F6.

• September 24, 2021, 7:59 PM ET debt materiality 0.75 positive item 1.01item 8.01item 9.01

  Regen Biopharma secures $1.39M net financing via $1.5M note, settles ChemDiv lawsuit for $800K

  Issued $1.5M promissory note to Coventry Enterprises LLC; net proceeds $1.39M after $75K OID and $35K fees.

• September 16, 2021, 7:59 PM ET litigation materiality 0.60 neutral item 1.01item 9.01

  Regen Biopharma settles ChemDiv lawsuit for $800k, contingent on SEC filing by Sept 24

  Regen to pay $800k lump sum by Sept 30, 2021, to settle ChemDiv's breach-of-contract lawsuit over ~$1.2M unpaid invoices.

• August 31, 2021, 7:59 PM ET other material materiality 0.30 positive item 8.01

  Regen Biopharma corrects convertible debt date, becomes current on SEC filings, plans to settle notes

  Corrects earlier statement: no convertible debt issued since July 2019, not July 2020.

• August 31, 2021, 7:59 PM ET other material materiality 0.50 neutral item 8.01

  Regen Biopharma files Q2 2021 10-Q, ends reporting delinquency; plans convertible debt settlement to curb dilution

  Filed quarterly report for period ended June 30, 2021; now current on SEC filings.

• August 26, 2021, 7:59 PM ET other material materiality 0.55 positive item 8.01

  Regen Biopharma receives U.S. patent for mRNA-based cancer vaccine technology

  USPTO issued Patent No. 11,090,332 B2 on August 17, 2021, for "Antigen Specific MRNA Cellular Cancer Vaccines".

• July 14, 2021, 7:59 PM ET other material materiality 0.30 neutral item 8.01

  Regen Biopharma begins audit of FY2020 financials to cure reporting delinquency

  BF Borgers CPA PC started audit of FY2020 financial statements on July 8, 2021.

• July 13, 2021, 7:59 PM ET other material materiality 0.40 neutral item 8.01

  Regen Biopharma discloses full IP portfolio status with patent grants, allowances, and revival efforts

  Granted US patents: BORIS gene silencing (8,263,571), NR2F6 anti-tumor methods (11,053,503), NR2F6 screening (10,088,485), NR2F6 modulation (9,091,696).

• July 2, 2021, 7:59 PM ET other material materiality 0.65 positive item 8.01

  Regen Biopharma subsidiary KCL receives USPTO patent grant for NR2F6 inhibition cancer therapy

  KCL Therapeutics (Regen Biopharma subsidiary) granted USPTO patent for NR2F6 inhibition method.

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.85 · Median 0.60 · Most common event other_material

10 positive 14 negative 25 neutral

source · RGBP on sec.gov